BIA’s health data vision 2035 report sets out how the UK can use consented and well-governed health data to drive economic growth, innovation and better patient outcomes.
In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.
The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.
With £1.46 billion raised since 2018 and a record recovery in 2025, the UK biosolutions sector is moving from lab-based experiments to industrial-scale impact. Explore the data behind the UK's next industrial revolution.
Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.
Charlotte Cane, MP for Ely and East Cambridgeshire, visited local life science companies on 31 March to see for herself how new medicines and medical technologies are being developed.
I’m pleased to share that we are part of a new Government and industry joint taskforce to drive innovation in the UK’s commercial environment for medicines, announced last week as part of government ambitions for the Life Sciences Strategy.
Senior figures from across industry, academia, investment and government met at the House of Lords, for a roundtable hosted by The Lord Ranger of Northwood to discuss the findings of a new report.
There are a number of significant moving pieces right now in the sector, including the major strategic shift at UKRI and Innovate launched last Thursday.
Glasgow’s newest purpose-built life sciences laboratory facility, the Health Innovation Hub (HiH), was officially opened by Wes Streeting, Secretary of State for Health and Social Care.
In this guest blog, Dr David Montgomery, co-founder of PM Life Sciences, discusses the reality of UK-originated assets, companies and long-term economic returns ending up overseas despite record public investment and a world-class discovery base.
In this blog, Emily Klein reflects on the importance of Rare Disease Day in bringing visibility to those affected by a rare condition and serving as a focal point for advocacy in this space.
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
In this guest blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
